The Infusion Drug Markup Problem: What Your Health Plan Is Overpaying — And How to Stop It

Most HR leaders and CFOs know their healthcare costs are rising. Fewer understand exactly why — and almost none know where the single largest, most actionable savings opportunity is hiding in their health plan.

It's not in your deductible structure. It's not in your carrier contract. 

It's in where your employees are receiving their infusions — and what your plan is being charged for the same drug, at the same dose, depending solely on which building the IV drip happens in.

This is the infusion drug markup problem. It costs employer health plans across the country tens of thousands of dollars per patient per year. And for the vast majority of employers, nobody is tracking it.

Specialty Drugs Are Now the Dominant Driver of Employer Pharmacy Spend

To understand infusion drug costs, also considered specialty drugs, we need to start with the bigger picture.

Specialty drugs now account for more than 51% of total pharmacy benefit plan costs, despite representing less than 2% of prescription claims, according to RxBenefits research published in Fierce Healthcare. For self-funded and level-funded employers, this isn't an abstract industry statistic. It shows up directly in your claims, concentrated among a small number of employees whose medications can cost more than most workers' total annual compensation.

What makes infusion drugs a particularly urgent concern is a compounding effect: the drugs themselves are expensive, and the setting in which they're administered can multiply the final bill by two, three, or even ten times — before the claim ever reaches your plan.

The Buy-and-Bill System and Why It's Working Against You

Infusion drugs — biologics and specialty therapies administered intravenously in a clinical setting — are priced and billed through a model the industry calls "buy-and-bill." Under this system, a provider purchases the drug, administers it to the patient, and bills the health plan at a marked-up rate above their acquisition cost.

For Medicare patients, reimbursement is regulated and capped. For commercial employer health plans, there is no equivalent ceiling. Hospitals bill what their contracts allow, and in most cases, employers have no visibility into what those rates are until the claim arrives.

The result is a dramatic and well-documented price disparity for identical care. A Bloomberg News investigation published in December 2025 put this in stark terms: one patient with colon cancer received her first chemotherapy infusion at a hospital, where the bill to her health plan was $13,560. Three weeks later, the same drug at a clinic within the same hospital system cost $134. As the patient put it: "Same drug, different prices. It's ridiculous."

That example isn't an outlier. Bloomberg's analysis of healthcare pricing data found that nearly 150 hospitals across the U.S. are charging commercial insurers five times the Medicare rate or more for routine infusion drugs. In one documented case, a union health plan was billed close to $90,000 for a series of infusions of a cancer drug that Medicare reimburses at roughly $35 per dose.

The pattern holds across infusion settings more broadly:

Site of Care	Example: Remicade Infusion
Physician office	~$4,000
Independent infusion center	~$5,500
Hospital outpatient department	$8,000–$12,000

The clinical outcome is the same at every site. The bill is not.

For employees, the markup is largely invisible. They pay their copay whether the drug costs the plan $300 or $13,000. The difference disappears into the premium increase you absorb at renewal, year after year, with no explanation attached.

The Infusion Drugs Your Health Plan Should Be Tracking Right Now

Not all infusion drugs carry equal markup risk. Benefits consultants and specialty pharmacy cost management specialists focus on a core group of medications that combine high per-dose cost with widespread employer plan utilization. These are the drugs most frequently identified in site-of-care optimization programs, and the ones most likely to be generating hidden overspend in your claims data today.

Immunology & Autoimmune Biologics

• Remicade (infliximab) — Crohn's disease, ulcerative colitis, rheumatoid arthritis; the single most commonly redirected drug in employer site-of-care programs

• Rituxan (rituximab) — rheumatoid arthritis and blood cancers

• Actemra (tocilizumab) — rheumatoid arthritis and inflammatory disease

Oncology

• Keytruda — the world's top-selling cancer immunotherapy; the list price for a standard 200 mg dose is approximately $11,700 per infusion, with patients often receiving treatment every three to six weeks, placing annual therapy costs well into six figures

• Opdivo — widely used PD-1 cancer immunotherapy, frequently infused in high-markup hospital settings

• Avastin / Herceptin — established oncology drugs that continue to generate significant infusion revenue for hospital outpatient departments

Neurology

• Ocrevus — multiple sclerosis, infused every six months

• Tysabri — multiple sclerosis, monthly infusion

Rare Disease

• Soliris — rare blood disorders; annual costs can exceed $500,000 per patient

In most mid-market employer health plans, just five of these drugs — Remicade, Rituxan, Keytruda, Ocrevus, and Opdivo — drive the majority of infusion spend. If your benefits partner isn't tracking these by name, by patient, and by site of care, your plan is almost certainly overpaying.

The Strategy That Changes the Outcome: Site-of-Care Optimization

Here's the good news: the infusion markup problem has a proven solution, and it doesn't require cutting benefits or restricting access to care.

Site-of-care optimization is the practice of identifying employees who are receiving infusions in high-cost hospital outpatient settings and, through clinical outreach and plan design, helping them access the same treatment at a lower-cost, equally effective site. For most of the drugs above, FDA-approved dosing, clinical protocols, and patient outcomes are identical regardless of where the infusion takes place.

According to a UnitedHealth Group estimate cited by the Infusion Providers Alliance, administering specialty drugs in a physician office or home setting instead of a hospital outpatient department reduces costs by $16,000 to $37,000 per privately-insured patient per year for the conditions that account for the majority of infusion spending. Hospital-based infusions can run two to five times the cost of the same treatment at an office or freestanding ambulatory site. The Bloomberg investigation cited the same dynamic: a union health plan caseworker helped a patient switch sites, eliminated her $100 copay entirely, and saved the plan significant dollars in the process. "I would've been stuck with a bill," the patient said of the previous arrangement.

That outcome — lower cost for the plan, better deal for the employee — is what a proactive specialty drug management strategy actually looks like.

Effective site-of-care programs include:

• Claims-based identification of employees on high-cost infusion medications

• Clinical outreach to patients and prescribing physicians about lower-cost site options

• Prior authorization requirements for hospital-based infusion when equivalent alternatives are available

• Member incentives that reward employees for choosing preferred sites — often eliminating their out-of-pocket cost entirely

This Is Exactly What the Rx Shield™ Program Was Built to Do

Most traditional benefits brokers don't track infusion spend by drug, by patient, or by site of care. The annual renewal cycle doesn't demand it, and without that visibility, the markup problem stays invisible year after year.

Evolve Benefits operates differently. 

Through Rx Shield™ at www.myrxshield.com, we bring employers the specialty drug intelligence that most health plans never see — and then build an actionable strategy around it.

Here's what Rx Shield does for your plan:

Identifies your top Rx spend drivers — We analyze your claims data to pinpoint which employees are on high-cost infusion and specialty drugs, what those medications are costing your plan, and where the treatments are being administered. Most employers are surprised by what the data reveals.

Reduces your top specialty Rx spend — Based on your specific claims profile, Rx Shield deploys targeted strategies: site-of-care optimization, specialty pharmacy carve-outs, biosimilar substitution programs, prior authorization management, and PBM contract review. Every strategy is built around your data, not a generic template.

Tracks and measures results year-round — Savings are documented in real time. Trends are monitored. Strategies are adjusted as your claims profile evolves. This is ongoing pharmacy cost management, not a once-a-year renewal conversation.

The employers who engage Evolve through Rx Shield don't just save money at the next renewal. They build a sustainable foundation for managing specialty drug spend over time — which, given the continued growth of the specialty pharmaceutical market, is exactly what's required to stay ahead of this cost curve.

The Bottom Line

The infusion drug markup problem is real, it is large, and it is almost entirely invisible to employers who aren't actively looking for it. A drug that costs a health plan $35 under Medicare rates being billed at hundreds or thousands of times that amount isn't a pharmaceutical pricing issue — it's a transparency and oversight issue. And it plays out quietly in employer health plans across the country every day.

The solution isn't to cut benefits. It's to see what's actually happening in your claims data and build a strategy around it.

That's what Rx Shield™ does. And that's what Evolve Benefits was built for.

Visit www.myrxshield.com to learn more — or reach out to Evolve directly to get a specialty drug analysis of your current plan. Your next renewal is coming. The time to build the strategy is now.

Sources: Bloomberg News, "One Generic Cancer Drug Costs $35. Or $134. Or $13,000." (December 17, 2025); RxBenefits / Fierce Healthcare, "Rising Drug Costs Are Threatening the Future of Employee Benefits" (August 2025); Infusion Providers Alliance, "Cost Savings and Improved Quality in a Clinic-Based Setting," citing UnitedHealth Group site-of-care estimates; Serif Health, "What Price Transparency Data Teaches Us About Keytruda" (August 2025).